Compare the safety & efficacy of Rosuvastatin 40mg in combination with Ezetimibe 10mg - EXPLORER
Study identifier:D3569C00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 6wk open-label, randomised, multicentre, phase IIIb, parallel group study to compare the safety & efficacy of Rosuvastatin 40mg in comb.with Ezetimibe 10mg in subjects with Hypercholesterolaemia & CHD or atherosclerosis or a CHD risk equiv. (10 yr risk score >20%).
Medical condition
Hypercholesterolemia
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin, Ezetimibe
Sex
All
Actual Enrollment
-
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jun 2004
Primary Completion Date: -
Study Completion Date: 01 Jun 2005
Study design
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Rosuvastatin 40mg/Ezetimibe 10mg combination therapy | Drug: Rosuvastatin 40mg Other Name: Crestor Drug: Ezetimibe 10mg Other Name: Zetia |
| Experimental: 2 Rosuvastatin 40 mg | Drug: Rosuvastatin 40mg Other Name: Crestor |
Contacts
Investigators
Principal Investigator
Christine Ballantyne
Centre for prevention of cardiovascular disease, Texas, USA
